NYSE:CBM - Cambrex Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $41.64 -0.79 (-1.86 %) (As of 12/14/2018 04:00 PM ET)Previous Close$41.64Today's Range$41.44 - $42.8152-Week Range$41.44 - $69.43Volume396,677 shsAverage Volume359,556 shsMarket Capitalization$1.42 billionP/E Ratio13.14Dividend YieldN/ABeta2.35 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey. Receive CBM News and Ratings via Email Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNYSE:CBM Previous Symbol CUSIP13201110 Webwww.cambrex.com Phone201-804-3000 Debt Debt-to-Equity Ratio0.49 Current Ratio4.54 Quick Ratio3.41 Price-To-Earnings Trailing P/E Ratio13.14 Forward P/E Ratio15.03 P/E Growth1.53 Sales & Book Value Annual Sales$534.46 million Price / Sales2.61 Cash Flow$4.1351 per share Price / Cash Flow10.07 Book Value$16.62 per share Price / Book2.51 Profitability EPS (Most Recent Fiscal Year)$3.17 Net Income$102.45 million Net Margins22.67% Return on Equity22.20% Return on Assets14.86% Miscellaneous Employees1,228 Outstanding Shares33,560,000Market Cap$1.42 billion OptionableOptionable Cambrex (NYSE:CBM) Frequently Asked Questions What is Cambrex's stock symbol? Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM." How were Cambrex's earnings last quarter? Cambrex Co. (NYSE:CBM) released its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported $0.49 EPS for the quarter, missing the consensus estimate of $0.59 by $0.10. The biotechnology company earned $104.62 million during the quarter, compared to analysts' expectations of $122.04 million. Cambrex had a net margin of 22.67% and a return on equity of 22.20%. The firm's revenue for the quarter was down 7.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.55 EPS. View Cambrex's Earnings History. When is Cambrex's next earnings date? Cambrex is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Cambrex. What guidance has Cambrex issued on next quarter's earnings? Cambrex issued an update on its FY 2018 earnings guidance on Thursday, November, 8th. The company provided earnings per share (EPS) guidance of $2.95-3.09 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.79. What price target have analysts set for CBM? 5 analysts have issued 1 year price objectives for Cambrex's shares. Their predictions range from $63.00 to $75.50. On average, they expect Cambrex's stock price to reach $69.25 in the next year. This suggests a possible upside of 66.3% from the stock's current price. View Analyst Price Targets for Cambrex. What is the consensus analysts' recommendation for Cambrex? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex. Has Cambrex been receiving favorable news coverage? Media headlines about CBM stock have trended somewhat positive recently, InfoTrie reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cambrex earned a coverage optimism score of 1.2 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future. Who are some of Cambrex's key competitors? Some companies that are related to Cambrex include GALAPAGOS NV/S (GLPG), Amarin (AMRN), Alkermes (ALKS), Catalent (CTLT), Amneal Pharmaceuticals (AMRX), United Therapeutics (UTHR), SAGE Therapeutics (SAGE), HUTCHISON CHINA/S (HCM), Loxo Oncology (LOXO), TESARO (TSRO), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), Array Biopharma (ARRY), FibroGen (FGEN) and Horizon Pharma (HZNP). Who are Cambrex's key executives? Cambrex's management team includes the folowing people: Mr. Steven M. Klosk, Pres, CEO & Director (Age 61)Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy and CFO (Age 52)Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 52)Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 40)Mr. Tom G. Vadaketh, Former Exec. VP & CFO (Age 55) Who are Cambrex's major shareholders? Cambrex's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.23%), Vanguard Group Inc (9.78%), Vanguard Group Inc. (9.78%), William Blair Investment Management LLC (7.54%), Bank of New York Mellon Corp (4.51%) and Dimensional Fund Advisors LP (4.22%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex. Which institutional investors are selling Cambrex stock? CBM stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Wells Fargo & Company MN, Tributary Capital Management LLC, Panagora Asset Management Inc., Janus Henderson Group PLC, Prudential Financial Inc., Rice Hall James & Associates LLC and Cambiar Investors LLC. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Insider Buying and Selling for Cambrex. Which institutional investors are buying Cambrex stock? CBM stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Acadian Asset Management LLC, William Blair Investment Management LLC, Castleark Management LLC, Clearbridge Investments LLC, Copper Rock Capital Partners LLC, Oak Ridge Investments LLC and LSV Asset Management. View Insider Buying and Selling for Cambrex. How do I buy shares of Cambrex? Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cambrex's stock price today? One share of CBM stock can currently be purchased for approximately $41.64. How big of a company is Cambrex? Cambrex has a market capitalization of $1.42 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe. What is Cambrex's official website? The official website for Cambrex is http://www.cambrex.com. How can I contact Cambrex? Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected] MarketBeat Community Rating for Cambrex (NYSE CBM)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 220 (Vote Outperform)Underperform Votes: 200 (Vote Underperform)Total Votes: 420MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/15/2018 by MarketBeat.com StaffFeatured Article: What are the economic characteristics of a bear market?